Zobrazeno 1 - 10
of 2 075
pro vyhledávání: '"JAK2 V617F"'
Autor:
O. Yu. Vinogradova, M. M. Pankraskina, A. L. Neverova, D. I. Shikhbabaeva, M. A. Murzabekova, M. V. Chernikov, A. V. Popova, V. P. Kosenkova, L. B. Egoryan, V. V. Ptushkin
Publikováno v:
Онкогематология, Vol 19, Iss 3, Pp 16-33 (2024)
Background. Currently, targeted therapy is the most promising for the treatment of myelofibrosis (MF). Today, the results of many years of experience with the use of ruxolitinib, including outside randomized trials and the identification of predictor
Externí odkaz:
https://doaj.org/article/32b92dd0c58149d28216d7e1ea000c8a
Autor:
Chie Asou, Tomoyuki Sakamoto, Kodai Suzuki, Itoko Okuda, Atsushi Osaki, Ryohei Abe, Yoshihiro Ito, Emi Kakegawa, Yoshitaka Miyakawa, Yasuhito Terui, Yuichi Nakamura
Publikováno v:
Journal of Medical Case Reports, Vol 18, Iss 1, Pp 1-5 (2024)
Abstract Background Blast transformation is a rare but well-recognized event in Philadelphia-negative myeloproliferative neoplasms associated with a poor prognosis. Secondary acute myeloid leukemias evolving from myeloproliferative neoplasms are char
Externí odkaz:
https://doaj.org/article/20ad831a1d844d00a58a9546ec999cd6
Publikováno v:
Global Medical Genetics, Vol 11, Iss 02, Pp 132-141 (2024)
Precise quantification of the JAK2V617F mutation using highly sensitive assays is crucial for diagnosis, treatment process monitoring, and prognostic prediction in myeloproliferative neoplasms' (MPNs) patients. Digital droplet polymerase chain reacti
Externí odkaz:
https://doaj.org/article/e185824e9a014d1295d9b1f57b8b07c3
Autor:
Velizar Shivarov, Gergana Tsvetkova, Ilina Micheva, Evgueniy Hadjiev, Jasmina Petrova, Anela Ivanova, Galia Madjarova, Milena Ivanova
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
It has been demonstrated previously that human leukocyte antigen class I (HLA-I) and class II (HLA-II) alleles may modulate JAK2 V617F and CALR mutation (CALRmut)-associated oncogenesis in myeloproliferative neoplasms (MPNs). However, the role of imm
Externí odkaz:
https://doaj.org/article/6a6deca4d4ff4b769557a724354ad0e5
Publikováno v:
eJHaem, Vol 5, Iss 1, Pp 157-161 (2024)
Abstract The simultaneous detection of BCR::ABL1 and JAK2 V617F was rarely reported and their clonal relationship and dynamic clonal shift were not characterized. Here, we described a unique case with the initial presentation as JAK2 V617F+ primary m
Externí odkaz:
https://doaj.org/article/b6bbe0ad9a914f62912730aeb05d1be9
Autor:
Tobias Idor Boklund, Jordan Snyder, Johanne Gudmand-Hoeyer, Morten Kranker Larsen, Trine Alma Knudsen, Christina Schjellerup Eickhardt-Dalbøge, Vibe Skov, Lasse Kjær, Hans C. Hasselbalch, Morten Andersen, Johnny T. Ottesen, Thomas Stiehl
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionThe Philadelphia chromosome-negative myeloproliferative neoplasms are a group of slowly progressing haematological malignancies primarily characterised by an overproduction of myeloid blood cells. Patients are treated with various drugs,
Externí odkaz:
https://doaj.org/article/d2e7c2148e984299bb4c140c1200e5d0
Publikováno v:
Journal of Inflammation Research, Vol Volume 16, Pp 4117-4121 (2023)
Jing Yuan, Xuan Liu, Zhenzhen Wang, Liyuan Li, Fuxu Wang Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, People’s Republic of ChinaCorrespondence: Fuxu Wang, Department of Hematology, The Seco
Externí odkaz:
https://doaj.org/article/f8bbaeab7fb648cc8e8c808044c1658c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jie Jin, Lei Zhang, Albert Qin, Daoxiang Wu, Zonghong Shao, Jie Bai, Suning Chen, Minghui Duan, Hu Zhou, Na Xu, Sujiang Zhang, Xuelan Zuo, Xin Du, Li Wang, Pei Li, Xuhan Zhang, Yaning Li, Jingjing Zhang, Wei Wang, Weihong Shen, Oleh Zagrijtschuk, Raymond Urbanski, Toshiaki Sato, Zhijian Xiao
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-5 (2023)
Abstract Ropeginterferon alfa-2b represents a new-generation pegylated interferon-based therapy and is administered every 2–4 weeks. It is approved for polycythemia vera (PV) treatment in the United States and Europe with a starting dose of 100 µg
Externí odkaz:
https://doaj.org/article/47da0a8a91504cafb29f590303295981